Targeting Angiogenesis in Childhood Sarcomas
Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Sarcoma |
Online Access: | http://dx.doi.org/10.1155/2011/601514 |
id |
doaj-4ce4523cedd74f2c94f7d7e444e8c109 |
---|---|
record_format |
Article |
spelling |
doaj-4ce4523cedd74f2c94f7d7e444e8c1092020-11-24T22:29:53ZengHindawi LimitedSarcoma1357-714X1369-16432011-01-01201110.1155/2011/601514601514Targeting Angiogenesis in Childhood SarcomasHemant K. Bid0Peter J. Houghton1Center for Childhood Cancer, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USACenter for Childhood Cancer, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USAAngiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.http://dx.doi.org/10.1155/2011/601514 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hemant K. Bid Peter J. Houghton |
spellingShingle |
Hemant K. Bid Peter J. Houghton Targeting Angiogenesis in Childhood Sarcomas Sarcoma |
author_facet |
Hemant K. Bid Peter J. Houghton |
author_sort |
Hemant K. Bid |
title |
Targeting Angiogenesis in Childhood Sarcomas |
title_short |
Targeting Angiogenesis in Childhood Sarcomas |
title_full |
Targeting Angiogenesis in Childhood Sarcomas |
title_fullStr |
Targeting Angiogenesis in Childhood Sarcomas |
title_full_unstemmed |
Targeting Angiogenesis in Childhood Sarcomas |
title_sort |
targeting angiogenesis in childhood sarcomas |
publisher |
Hindawi Limited |
series |
Sarcoma |
issn |
1357-714X 1369-1643 |
publishDate |
2011-01-01 |
description |
Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers. |
url |
http://dx.doi.org/10.1155/2011/601514 |
work_keys_str_mv |
AT hemantkbid targetingangiogenesisinchildhoodsarcomas AT peterjhoughton targetingangiogenesisinchildhoodsarcomas |
_version_ |
1725742859878924288 |